Singapore, July 6 -- TELIX PHARMACEUTICALS LIMITED made the following announcement:
Security Name: TELIXPHAR A$650M2.375%N290730
General Announcement::ASX:NASDAQ:TLX: FDA Alignment to Advance ProstACT Global Phase 3 Trial (https://links.sgx.com/1.0.0/corporate-announcements/OOFTPCR5GGVTQS0T/094942df049f37003a2c8020e657a6c091d9eb4af1251c70805217615eea472b)
Published by HT Digital Content Services with permission from South East Asian News....